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Abstract
Hypoxia-inducible factor-1 (HIF-1) is a key regulator of
genes crucial to many aspects of cancer biology. The
purine nucleoside, adenosine, accumulates within
many tissues under hypoxic conditions, including that
of tumors. Because the levels of both HIF-1 and adeno-
sine are elevated within the hypoxic environment of
solid tumors, we investigated whether adenosine may
regulate HIF-1. Here we show that, under hypoxic
conditions (< 2% O2), adenosine upregulates HIF-1A
protein expression in a dose-dependent and time-
dependent manner, exclusively through the A3 recep-
tor subtype. The response to adenosine was generated
at the cell surface because the inhibition of A3 receptor
expression, by using small interfering RNA, abolished
nucleoside effects. A3 receptor stimulation in hypoxia
also increases angiopoietin-2 (Ang-2) protein accumu-
lation through the induction of HIF-1A. In particular,
we found that A3 receptor stimulation activates p44/
p42 and p38 mitogen-activated protein kinases, which
are required for A3-induced increase of HIF-1A and
Ang-2. Collectively, these results suggest a coopera-
tion between hypoxic and adenosine signals that
ultimately may lead to the increase in HIF-1–mediated
effects in cancer cells.
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Introduction
Adenosine is a ubiquitous autacoid that accumulates to high
levels in hypoxic tissues as a result of ATP breakdown
[1–4]. Therefore, this nucleoside could be involved in the
regulation of the cellular response to hypoxia. In particular, it
is recognized that significant levels of adenosine are pres-
ent in the extracellular fluid of solid tumors [5], suggesting a
role for this autacoid in tumor growth. However, it was only
recently that adenosine has been shown to be a crucial
factor in determining the cell progression pathway, either in the
apoptotic state or the cytostatic state [6,7].
Adenosine modulates a variety of cellular functions through
occupancy of four cell surface G-protein–coupled receptors,
named A1, A2A, A2B, and A3 [8,9]. In particular, adenosine was
found to exert its effects on cell proliferation, clone formation
ability, UV resistance, and cell death mainly through the
A3 subtype [10–13], which is highly expressed in tumor
cells [14–18]. These findings confirm recent data indicating
that A3 receptor overexpression may be a good candidate as a
tumor cell marker [18,19]. Adenosine also plays a role in the
promotion of angiogenesis [20,21]. The regulation of expres-
sion of the angiogenic vascular endothelial growth factor
(VEGF) through adenosine receptors has been demonstrated
in several cell types [22–25].
Hypoxia-inducible factor (HIF)-1 is a transcription factor that
functions as a master regulator of oxygen homeostasis [26].
HIF-1 is a heterodimer composed of an inducibly expressed
HIF-1a subunit and a constitutively expressed HIF-1b subunit
[27]. HIF-1a and HIF-1b mRNA are constantly expressed
under normoxic and hypoxic conditions [28]. During normoxia,
HIF-1a is rapidly degraded by the ubiquitin proteasome sys-
tem, whereas exposure to hypoxic conditions prevents its
degradation [29,30]. However, aberrant HIF-1a expression
could be caused by mutations in the HIF-1a gene itself or its
Abbreviations: Act-D, actinomycin D; Ang-2, angiopoietin-2; CHX, cycloheximide; Cl-IB-
MECA, N 6(3-iodobenzyl)2-chloroadenosine-5VN-methyluronamide; DPCPX, 1,3-dipropyl-8-
cyclopentylxanthine; HIF-1, hypoxia-inducible factor-1; MAPK, mitogen-activated protein
kinase; MEK, mitogen-activated protein kinase kinase; MRE 3008F20, 5N-(4-methoxyphenyl-
carbamoyl)amino-8-propyl-2-(2-furyl)-pyrazolo-[4,3e]1,2,4-triazolo[1,5c]pyrimidine; MRE
2029F20, N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-
yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide; RT-PCR, reverse transcription polymerase chain
reaction; SCH 58261, 7-(2-phenylethyl)2-(2-furyl)pyrazolo[4,3e]1,2,4-triazolo[1,5c]pyrimidine;
siRNA, small interfering RNA; siRNAA3, small interfering RNA targeting A3 receptor mRNA;
siRNAHIF-1a, small interfering RNA targeting HIF-1a mRNA; VEGF, vascular endothelial
growth factor
Address all correspondence to: Prof. Pier Andrea Borea, Department of Clinical and
Experimental Medicine—Pharmacology Unit, Via Fossato di Mortara 17-19, Ferrara 44100,
Italy. E-mail: bpa@dns.unife.it
Received 29 April 2005; Revised 30 May 2005; Accepted 1 June 2005.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.05334
Neoplasia . Vol. 7, No. 10, October 2005, pp. 894 –903 894
www.neoplasia.com
RESEARCH ARTICLE
regulating pathways, leading to hypoxia-independent ex-
pression of HIF-1a [31,32].
A growing body of evidence indicates that HIF-1 contrib-
utes to tumor progression and metastasis [33,34]. Immuno-
histochemical analyses have shown that HIF-1a is present in
higher levels in human tumors than in normal tissues [35]. In
particular, the levels of HIF-1 activity in cells are correlated
with tumorigenicity and angiogenesis in nude mice [36].
Tumor cells lacking HIF-1 expression are markedly impaired
in their growth and vascularization [37–40]. Therefore, be-
cause HIF-1a expression and activity appear central to
tumor growth and progression, HIF-1 inhibition becomes
an appropriate anticancer target [26,40,41].
Production of adenosine in hypoxia has not yet been
related to HIF-1a. The aim of this study is to determine
whether or not extracellular adenosine might serve as an
endogenous, physiological regulator of HIF-1a in hypoxia.
Furthermore, as HIF-1a plays a key role in inducing angio-
genesis [20–25], we have also studied the role of adenosine
in mediating the production of VEGF and angiopoietin-2
(Ang-2) in hypoxic cells.
Materials and Methods
Cell Lines, Reagents, and Antibodies
NCTC 2544 keratinocytes, and A375 melanoma, HT29
colon carcinoma, MCF-7 breast carcinoma, OVCAR-3 ovary
carcinoma, U2OS osteosarcoma, and U87MG glioblastoma
human cells were obtained from the American Tissue
Culture Collection (ATCC; Manassas, VA). Tissue culture
media and growth supplements were obtained from Bio-
Whittaker (Bergamo, Italy). The GasPak Pouch System was
obtained from Becton Dickinson (Milan, Italy). Anti–HIF-1a
and anti–HIF-1b antibodies were obtained from Transduc-
tion Laboratories (BD; Milan, Italy). U0126 [inhibitor of
mitogen-activated protein kinase kinase (MEK)-1 and
MEK-2], SB202190 (inhibitor of p38 MAP kinase), anti–
ACTIVE mitogen-activated protein kinase (MAPK), and
anti–ERK 1/2 (pAb) were from Promega (Milan, Italy).
Lamin A, phospho-p38, and p38 MAP kinase antibodies
were from Cell Signaling Technology (Celbio; Milan, Italy).
Anti–adenosine A2A receptor (pAb) was from Santa Cruz
Biotechnology (RBA; Milan, Italy). Anti–adenosine A3 re-
ceptor (polyAb) was from Aviva Antibody Corporation (RBA;
Milan, Italy). Unless otherwise noted, all other chemicals
were purchased from Sigma (Milan, Italy).
Cell Culture and Hypoxia Treatment
Cells were maintained in DMEM (A375, HT-29, and MCF-
7), EMEM (NCTC 2544) or RPMI 1640 (OVCAR-3, U87MG,
and U2OS) medium containing 10% fetal calf serum, penicillin
(100 U/ml), streptomycin (100 mg/ml), and L-glutamine (2 mM)
at 37jC in 5%CO2/95% air. Cells were passaged two or three
times weekly at a ratio between 1:5 and 1:10. Hypoxic expo-
sure was performed using the BBL GasPak pouch System
(Becton Dickinson) that reduces the oxygen concentration at
less than 2% within 2 hours of incubation at 37jC.
RNA Interference
To generate four small interfering RNA targeting A3 re-
ceptor mRNA (siRNAA3), eight oligonucleotides were syn-
thesized and annealed, according to the manufacturer’s
instructions (Silencer siRNA Construction Kit; Ambion,
Milan, Italy) and as previously described [42]. Target se-
quences were aligned to the human genome database in a
BLAST search to ensure sequences without significant ho-
mology to other genes. The target sequences for oligo-1,
oligo-2, oligo-3, and oligo-4 are localized at positions 337,
679, 1009, and 1356 downstream of the start codon of A3
receptor mRNA sequence (L20463), respectively.
A375 cells were plated in six-well plates and grown to
50% to 70% confluence before transfection. Transfection of
siRNA was performed at a concentration of 100 nM using the
RNAiFect Transfection Kit (Qiagen, Milan, Italy). To quantify
cell transfection efficiency, we used siRNA FITC (Qiagen).
After 24 hours of transfection, cells were trypsinized and
resuspended in PBS for flow cytometry analysis. Fluores-
cence obtained from siRNA–FITC–transfected cells was
compared to autofluorescence generated by untransfected
control. A nonspecific control ribonucleotide sense strand
(5V-ACU CUA UCU GCA CGC UGA CdTdT-3V) and an anti-
sense strand (5V-dTdT UGA GAU AGA CGU GCG ACU G-
3V) were used under identical conditions.
Small interfering RNA targeting HIF-1amRNA (siRNAHIF-1a)
were synthesized and experiments were performed as pre-
viously described [43]. The sequences target nt 1378 to 1398
of the human HIF-1a mRNA (accession no. AF304431.1).
Flow Cytometry Analysis
A375 adherent cells were trypsinized, mixed with floating
cells, washed with PBS, and permeabilized in 70% (vol/vol)
ethanol/PBS solution at 4jC for at least 24 hours. The cells
were washed with PBS and the DNA was stained with a PBS
solution, containing 20 mg/ml propidium iodide and 100 mg/ml
RNAse, at room temperature for 30 minutes. Cells were ana-
lysed with an EPICS XL flow cytometer (Beckman Coulter,
Miami, FL) and the content of DNA was evaluated. Cell dis-
tribution among cell cycle phases and the percentage of
apoptotic cells were evaluated as previously described [10].
Briefly, the cell cycle distribution is shown as the percentage
of cells containing 2n (G0/G1 phases), 4n (G2 and M phases),
4n >x >2n DNA amounts (S phase) judged by propidium
iodide staining. Apoptotic population is the percentage of
cells with DNA content lower than 2n.
Real-Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR) Experiments
Total cytoplasmic RNA was extracted by the guanidinium
thiocyanate phenol method, as previously described [18].
Quantitative real-time RT-PCR assay [18] of HIF-1a and A3
mRNA transcripts was carried out using gene-specific
double fluorescently labeled TaqMan MGB probe (minor
groove binder) in an ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Warrington Cheshire, UK).
The following primer and probe sequences were used for
real-time RT-PCR: A3 forward primer, 5V-ATG CCT TTG
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GCC ATT GTT G-3V; A3 reverse primer, 5V-ACA ATC CAC
TTC TAC AGC TGC CT-3V; A3 MGB probe, 5V-FAM-TCA
GCC TGG GCA TC-TAMRA-3V; for the real-time RT-PCR of
the HIF-1a gene, the assays-on-demand gene expression
product accession no. NM 019 058 was used (Applied
Biosystems, Monza, Italy). The fluorescent reporter FAM
and the quencher TAMRA are 6-carboxy fluorescein and
6-carboxy-N,N,NV,NV-tetramethylrhodamine, respectively.
For the real-time RT-PCR of the reference gene, the endoge-
nous control human b-actin kit was used, and the probe was
fluorescent-labeled with VIC (Applied Biosystems).
Western Blot Analysis
A375, HT29, MCF-7, NCTC 2544, OVCAR-3, U2OS, and
U87MG cells were treated with adenosine or adenosine
analogues and exposed to normoxia and hypoxia for differ-
ent times (2–24 hours). Western blot analysis was per-
formed as previously described [10]. Membranes were
incubated with antibodies against HIF-1a (1:250 dilution)
and HIF-1b (1:1000 dilution) overnight at 4jC. Aliquots of
total protein sample (50 mg) were analyzed using antibodies
specific for phosphorylated (Thr183/Tyr185) or total p44/p42
MAPK (1:5000 dilution), phosphorylated (Thr180/Tyr182) or
total p38 MAPK (1:1000 dilution), and A3 receptor (1 mg/ml
dilution). Specific reactions were revealed with the enhanced
chemiluminescence Western blot analysis detection reagent
(Amersham Corp., Arlington Heights, IL). The membranes
were then stripped and reprobed with tubulin (1:250) to
ensure equal protein loading.
Enzyme-Linked Immunosorbent Assay (ELISA)
The levels of VEGF and Ang-2 protein secreted by the
cells in the medium were determined by an ELISA kit (R&D
Systems, Milan, Italy). In brief, subconfluent cells were
changed into fresh medium in the presence of solvent or
various concentrations of adenosine analogues for 24 or
48 hours in hypoxia. The medium was collected, and protein
concentrations were measured by ELISA according to the
manufacturer’s instructions. The results were normalized to
the number of cells per plate. The data were presented as
mean ± SD from three independent experiments.
Statistical Analysis
All values in the figures and text are expressed as mean
± SE of n observations (with n z 3). Data sets were
examined by analysis of variance (ANOVA) and Dunnett’s
test (when required). A P value less than .05 was considered
statistically significant.
Results
Adenosine Induces HIF-1a Protein Accumulation in Hypoxia
We have evaluated the biologic effect produced by
prolonged oxygen deprivation in the human A375 mela-
noma cell line. Viability and proliferation of A375 cells
exposed to hypoxia for 24 hours were assessed by ana-
lyzing the percentage of apoptotic cells and the distribution
among the different phases of the cell cycle. We employed
flow cytometry and DNA staining by propidium iodide for
discrimination of cells in apoptosis, in G0/G1, S, and G2/M
phases. The results indicated that hypoxia did not promote
significant cell death while interfering with proliferation by
arresting melanoma cells in the G0/G1 phase and reducing
the number of cells in the S and G2/M phases (Figure 1).
These data were confirmed by using trypan blue exclusion,
cell counts, and [3H]thymidine incorporation assay (data
not shown).
Exposure of human melanoma A375 cells to hypoxia led
to HIF-1a protein expression (Figure 2A). To study the effect
of adenosine on the transcription factor HIF-1, A375 cells
were treated for 4 hours in hypoxic conditions with increasing
concentrations of the nucleoside. Hypoxia alone increased
HIF-1a over normoxia. Adenosine further increased HIF-1a
protein expression in a time-dependent and dose-dependent
manner, with an EC50 = 2.1 ± 0.2 mM and a maximal increase
of 2.6 ± 0.2–fold at 100 mM (Figure 2B). We did not observe
any modulation of HIF-1b protein.
The family of adenosine receptors consists of four sub-
types of G-protein–coupled receptors, designated A1, A2A,
A2B, and A3 [8,9]. We have previously demonstrated that all
four adenosine receptors are expressed in A375 cells [15].
To evaluate the functional role of adenosine receptor sub-
types on HIF-1a protein expression under hypoxic condi-
tions, we tested the effect of adenosine in combination
with DPCPX (1,3-dipropyl-8-cyclopentylxanthine; an A1
Figure 1. Apoptosis and cell cycle analysis of A375 cells cultured in normoxia
or hypoxia for 24 hours. (A) Representative flow cytometric analysis of cell
cycle using propidium iodide for DNA staining; shown is the pattern of A375
cells being in apoptosis and in the G0/G1, S, and G2/M phases during
normoxia and hypoxia. Apoptotic cells (Apo) with subdiploid DNA content are
reported. (B) The quantitative analysis of subdiploids and cells in the G0/G1,
S, and G2/M phases is given in the graph. Plots are mean ± SE values (n = 3).
*P < .01 compared with normoxia.
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receptor antagonist), SCH 58261 [7-(2-phenylethyl)2-(2-fur-
yl)pyrazolo[4,3e]1,2,4-triazolo[1,5c]pyrimidine; a selective
A2A receptor antagonist], MRE 2029F20 [N-benzo[1,3]-
dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-
1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide; a
selective A2B receptor antagonist], and MRE 3008F20 [5N-
(4-methoxyphenyl-carbamoyl)amino-8-propyl-2-(2-furyl)-
pyrazolo-[4,3e]1,2,4-triazolo[1,5c]pyrimidine; a selective
A3 receptor antagonist] [15,44,45]. Although the A1, A2A,
and A2B receptor antagonists were not able to prevent
Figure 2. Induction of HIF-1a expression by adenosine and A3 receptors. (A) A375 cells were treated without (lane 1, control) or with adenosine at concentrations
of 10 nM (lane 2), 100 nM (lane 3), 1 M (lane 4), 10 M (lane 5), and 100 M (lane 6) in hypoxia for 4 hours. (B) The mean densitometry data were normalized to
the result obtained in hypoxic cells in the absence of adenosine (control). Plots are mean ± SE values (n = 3). (C) A375 cells were treated without (lane 1, control)
or with 100 M adenosine (lanes 2–6), and exposed to 100 nM DPCPX (lane 3), 100 nM SCH 58261 (lane 4), 100 nM MRE 2029F20 (lane 5), or 100 nM MRE
3008F20 (lane 6) in hypoxia for 4 hours. (D) The mean densitometry data from five independent experiments were normalized to the result obtained in cells in the
absence of adenosine (control). Plots are mean ± SE values (n = 5). *P < .01 compared with the control. (E) Induction of HIF-1 expression by A3 receptor
stimulation: time course. Cl-IB-MECA was 100 nM. (F) The mean densitometry data from three independent experiments were normalized to the result obtained in
cells in the absence of Cl-IB-MECA after 4 hours of hypoxia (control). Plots are mean ± SE values (n = 3). *P < .01 compared with the control. (G) Induction of HIF-
1a expression by A3 receptor stimulation: dose response. A375 cells were treated without (lane 1) or with Cl-IB-MECA at concentrations of 0.1 nM (lane 2), 1 nM
(lane 3), 10 nM (lane 4), 100 nM (lane 5), and 1 M (lane 6) in normoxia and hypoxia for 4 hours. (H) The mean densitometry data from 12 independent
experiments were normalized to the result obtained in cells in the absence of Cl-IB-MECA (control). Plots are mean ± SE values (n = 3). (I) Effect of A3 receptor
antagonist, MRE 3008F20. A375 cells were treated in hypoxia for 4 hours without (lane 1) or with 10 nM Cl-IB-MECA (lanes 2–6) and MRE 3008F20 at
concentrations of 0.3 nM (lane 3), 1 nM (lane 4), 3 nM (lane 5), and 10 nM (lane 6). (J) The mean densitometry data from three independent experiments were
normalized to the result obtained in cells in the absence of Cl-IB-MECA (control). Plots are mean ± SE values (n = 3).
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adenosine-induced HIF-1a protein accumulation, the A3 re-
ceptor antagonist, MRE 3008F20, abrogated the adenosine-
induced increase of HIF-1a protein expression (Figure 2,
C and D). Furthermore, HIF-1b expression was unaffected
by synthetic adenosine receptor antagonists. These results
indicate that adenosine may increase HIF-1a protein expres-
sion through A3 receptors.
A3 Adenosine Receptor Induces HIF-1a Protein
Accumulation in Hypoxia
To verify the involvement of A3 receptors in the modula-
tion of HIF-1a protein expression, we treated different tumor
cell lines with the selective A3 receptor agonist, Cl-IB-MECA
[N6(3-iodobenzyl)2-chloroadenosine-5VN-methyluronamide]
[46]. Here, we show the results obtained on the A375
melanoma cell line. We performed a time course experiment
in which A375 cells were exposed to 100 nM Cl-IB-MECA for
2 to 24 hours. A3 adenosine receptor stimulation did not
promote HIF-1a protein accumulation in normoxia, whereas
under hypoxic conditions, HIF-1a protein expression was
increased in a time-dependent manner (Figure 2, E and F ).
As already observed with adenosine, Cl-IB-MECA did not
modify HIF-1b expression in normoxia or hypoxia. Further
experiments found that Cl-IB-MECA was a very potent
agonist, having an EC50 of 10.6 ± 1.2 nM (Figure 2, G and
H ), consistent with an effect through adenosine A3 receptors.
The potency of the A3 receptor antagonist, MRE 3008F20,
was quantified. Increasing concentrations of MRE 3008F20
(0.3–30 nM) were able to inhibit HIF-1a protein accumula-
tion induced by a submaximal dose (10 nM) of Cl-IB-MECA
with an IC50 of 0.90 ± 0.08 nM (Figure 2, I–J ). Other
selective A3 antagonists (a series of substituted pyrazolotria-
zolopyrimidine derivatives) [47] also blocked Cl-IB-MECA–
induced HIF-1a accumulation (data not shown).
Finally, to further demonstrate that the A3 receptor is
required for HIF-1a protein accumulation in response to
adenosine, A375 cells were transfected with small interfer-
ing RNA that target A3 receptor mRNA (siRNAA3) for degra-
dation. The transfection efficiency of A375 cells, determined
by an siRNA control labeled with fluorescein, was monitored
(86.5%; Figure 3A). After 24, 48, and 72 hours posttransfec-
tion, A3 receptor mRNA and protein levels were significantly
reduced in siRNAA3-treated cells (Figure 3, B–D). To confirm
the specificity of the siRNAA3-mediated silencing of A3 re-
ceptor, we investigated the expression of A2A receptor
protein in siRNAA3-treated cells (Figure 3C). Figure 3C dem-
onstrates that treatment of A375 cells with siRNAA3 reduced
the expression of A3 protein but had no effect on the ex-
pression of A2A receptor. At 72 hours from the siRNAA3
transfection, A375 cells were exposed to increasing concen-
trations of Cl-IB-MECA (1–100 nM) for 4 hours in hypoxia.
We found that the inhibition of A3 receptor expression is suf-
ficient to block Cl-IB-MECA–induced HIF-1a accumulation
(Figure 3, E and F ).
To determine whether the effect of A3 receptor stimulation
on HIF-1a expression was a general phenomenon, we as-
sessed the ability of Cl-IB-MECA to induce HIF-1a levels in a
variety of cell lines expressing A3 adenosine receptors [7].
After 4 hours of hypoxia under Cl-IB-MECA treatment,
we were able to detect a significant increase of HIF-1a
protein expression in human keratinocytes (NCTC 2544)
and in different human tumor cells (HT29 colon carcinoma,
Figure 3. A3 receptor expression silencing by siRNA transfection. (A) Analysis of siRNA transfection efficiency in A375 cells. Representative flow chromatograms
of siRNA–FITC accumulation (gray filled area) in A375 cells transfected with siRNA–FITC. Unfilled area shows A375 cells transfected with RNAiFect Transfection
reagent without siRNA–FITC. Fluorescence was quantified by flow cytometry 5 hours posttransfection. (B) Relative A3 receptor mRNA quantification related to
-actin mRNA by real-time RT-PCR. A375 cells were transfected with siRNAA3 by the RNAiFect Transfection reagent and cultured for 24, 48, and 72 hours. Plots
are mean ± SE values (n = 3). *P < .01 compared with the control (time 0). (C) Western blot analysis using an anti –A3 receptor polyclonal antibody and an anti –A2A
receptor polyclonal antibody of protein extracts from A375 cells treated with scramble () or siRNAA3 (+) and cultured for 24, 48, and 72 hours. Tubulin shows equal
loading protein. (D) Densitometric quantification of A3 receptor Western blot analysis; plots are mean ± SE values (n = 5). *P < .01 compared with the control
(scramble transfected cells). (E) Western blot analysis using an anti –HIF-1a monoclonal antibody of protein extracts from A375 cells treated with scramble () or
siRNAA3 (+) for 72 hours and cultured without (lane 1) or with Cl-IB-MECA at concentrations of 10 nM (lanes 2 and 3) and 100 nM (lanes 4 and 5) for 4 hours in
hypoxia. Tubulin shows equal loading protein. (F) Densitometric quantification of HIF-1a Western blot analysis presented in panel E; plots are mean ± SE values
(n = 5). *P < .01 compared with the control (lane 1).
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MCF-7 breast carcinoma, OVCAR-3 ovarian carcinoma,
U87MG glioblastoma, and U2OS osteosarcoma; Figure 4).
A3 Receptor Mediates HIF-1a Accumulation through a
Transcription-Independent and Translation-Dependent
Pathway
We investigated by real-time RT-PCR experiments if
transcription of HIF-1a mRNA was modulated. Activation of
A3 receptors in hypoxic melanoma cells with 10/100/1000 nM
Cl-IB-MECA produced, respectively, a 1.13 ± 0.10–, 1.25 ±
0.15– , and 1.19 ± 0.13– fold change of HIF-1a mRNA
accumulation with respect to the corresponding untreated
cells, suggesting that A3 receptor stimulation does not reg-
ulate HIF-1a mRNA transcription. To confirm this hypothe-
sis, A375 cells were pretreated with 10 mg/ml actinomycin D
(Act-D) to inhibit de novo gene transcription. We found that
A3 receptor stimulation was able to increase HIF-1a protein
expression also in the presence of Act-D (Figure 5, A and B).
Next, we determined if A3 receptor induces HIF-1a ex-
pression through a translation-dependent pathway. In cells
exposed to 1 mM cycloheximide (CHX), 100 nM Cl-IB-MECA
failed to increase HIF-1a levels within 6 hours (Figure 5, C
and D).
These results suggest that A3 receptor activation
increases HIF-1a protein levels through a transcription-
independent and translation-dependent pathway.
After the return of hypoxic A375 cultures to normoxia, the
levels of HIF-1a protein decreased very rapidly (Figure 5E ).
In particular, a decrease in HIF-1a protein could be seen in
the absence and in the presence of Cl-IB-MECA with un-
changed degradation rate (Figure 5F ). These results indicate
that A3 receptor activation may not be able to significantly
prevent HIF-1a degradation in normoxic conditions.
Main Intracellular Signaling Pathways Sustained by A3
Receptors during HIF-1a Accumulation in Hypoxia
To determine whether the MAPK pathway was required
for HIF-1a protein increase induced by A3 receptor activa-
tion, A375 cells were pretreated with U0126, which is a
potent inhibitor of MEK1/2 [48], or with the inhibitor of p38
MAPK, SB202190 [49]. Cells were then exposed to 100 nM
Cl-IB-MECA for 4 hours in hypoxia. As shown in Figure 6A,
both U0126 (10 mM) and SB202190 (10 mM) were able
to inhibit the Cl-IB-MECA–induced increase of HIF-1a pro-
tein expression. These results suggest that p44/p42 and
Figure 4. A3 receptor stimulation induces HIF-1a accumulation in various
human cell lines under hypoxia. NCTC 2544 keratinocytes, and U87MG
glioblastoma, U2OS osteosarcoma, HT29 colon carcinoma, OVCAR-3
ovarian carcinoma, and MCF-7 breast carcinoma cells were treated without
() or with (+) 100 nM Cl-IB-MECA in hypoxia for 4 hours. Cellular extracts
were prepared and subjected to immunoblot assay using an anti –HIF-1a
monoclonal antibody. The blot was then stripped and used to determine HIF-
1 expression using an anti –HIF-1 monoclonal antibody.
Figure 5. A3 receptor stimulation induces HIF-1a accumulation through a transcription-independent and transduction-dependent pathway. (A) A375 cells were
pretreated with Act-D (10 g/ml) for 30 minutes and then exposed to 4 hours of hypoxia without () or with (+) 100 nM Cl-IB-MECA. (B) The mean densitometry
data from three independent experiments were normalized to the result obtained in cells in the absence of Cl-IB-MECA after 4 hours of hypoxia (control, lane 1).
Plots are mean ± SE values (n = 3). *P < .01 compared with the control. (C) HIF-1a accumulation was induced by the exposure of A375 cells to 100 nM Cl-IB-MECA
(+) for 4 or 6 hours in the absence (lanes 1 and 2) or in the presence (lanes 3 and 5) of 1 M CHX. (D) The mean densitometry data from three independent
experiments were normalized to the result obtained in cells in the absence of Cl-IB-MECA after 4 hours of hypoxia (control, lane 1). Plots are mean ± SE values
(n = 3). *P < .01 compared with the control. (E) A375 cells were incubated in hypoxia in the absence or in the presence of 100 nM Cl-IB-MECA. After 4 hours,
melanoma cells were exposed to normoxia and a time course of HIF-1a disappearance was performed at 0, 5, 10, and 15 minutes. (F) The mean densitometry data
from three independent experiments were normalized to the result obtained at time 0 (control). The fraction of remaining HIF-1a is indicated.
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p38 MAPK activity was required for the HIF-1a expression
increase induced by A3 receptor activation. Furthermore, to
confirm that p44/p42 and p38 MAPK belong to the signaling
pathways utilized by A3 receptor stimulation, we also inves-
tigated endogenous p44/p42 and p38 MAPK activation
levels in response to A3 receptor agonist treatment.
p44/p42 kinase phosphorylation status was maximal follow-
ing the treatment of 100 nM Cl-IB-MECA (Figure 6D),
whereas the phosphorylation of p38 MAPK increased in a
dose-dependent manner (Figure 6F ).
Modulation of VEGF and Ang-2 Expression
To investigate whether induction of HIF-1a expression by
A3 receptor stimulation in hypoxia results in a further in-
crease in HIF-1–regulated gene expression, the level of
VEGF protein in A375 cells after exposure to the A3 agonist,
Cl-IB-MECA, was analyzed using ELISA. Treatment of cells
with increasing concentrations of Cl-IB-MECA did not signifi-
cantly modulate VEGF levels, when compared with VEGF
levels in untreated hypoxic cells (Figure 7A).
On the contrary, treatment of cells with increasing con-
centrations of Cl-IB-MECA in hypoxia for 24 hours signifi-
cantly increased Ang-2 levels. In particular, Cl-IB-MECA was
able to increase Ang-2 levels up to 35% with respect to
untreated hypoxic cells (Figure 7B).
HIF-1a Knockdown Prevented the A3 Receptor–Induced
Increase of Ang-2
To determine if the increased levels of Ang-2 seen in
hypoxia after A3 receptor stimulation were a result of the
raised levels of HIF-1a, siRNAHIF-1awere directly transfected
into A375 cells 48 hours prior to exposure to Cl-IB-MECA
(500 nM) for 24 hours in hypoxia. When HIF-1a protein was
knocked down with siRNA (at 72 hours post–siRNAHIF-1a
transfection; Figure 7, C and D), Ang-2 protein increase in-
duced by A3 receptor stimulation was prevented (Figure 7E).
A3 Receptor Mediates Ang-2 Accumulation in Hypoxia
through a MAPK Pathway
The selective A3 antagonist, MRE 3008F20 (10 nM),
inhibited the Cl-IB-MECA–stimulated Ang-2 protein expres-
sion (Figure 7E ). To investigate whether the MAPK pathway
was involved in the expression of A3-induced Ang-2 protein,
A375 cells were cultured in hypoxia for 24 hours following
the addition of the MEK1/2 inhibitor, U0126, or with the inhibi-
tor of p38 MAPK, SB202190, 30 minutes prior to the treat-
ment of Cl-IB-MECA. As shown in Figure 7E, U0126 and
SB202190 (10 mM) significantly inhibited the Ang-2 protein
levels induced by Cl-IB-MECA.
Discussion
This is the first report that describes the role of adenosine
in modulating cellular response during hypoxia in an O2-
sensitive cell.
Hypoxia creates conditions that, on one hand, are condu-
cive to the accumulation of extracellular adenosine and, on
the other hand, stabilize HIFs, such as HIF-1a [1–4,29,30].
We demonstrate that adenosine is able to increaseHIF-1a
protein expression in response to hypoxia in a dose-
dependent and time-dependentmanner inA375humanmela-
noma cells, whereas HIF-1b protein levels are not affected.
We have previously demonstrated that all four adenosine
receptors are expressed in humanmelanomaA375 cells [15].
Here, we report that A3 receptor subtype mediates the ob-
served adenosine effects onHIF-1a regulation in this cell line.
Figure 6. Role of p38, p44, and p42 MAPKs in A3 signalling. (A) A375 cells were pretreated with or without 10 M U0126 or 10 M SB202190, and then exposed to
100 nM Cl-IB-MECA (+) for 4 hours in hypoxia. (B) The mean densitometry data from three independent experiments were normalized to the results obtained in
hypoxic cells in the absence of Cl-IB-MECA (lane 1). Plots are mean ± SE values (n = 3). *P < .01 compared with the control. (C) pp44 and pp42 MAPK protein
levels under A3 receptor stimulation: Cl-IB-MECA at concentrations of 0 nM (lane C), 10 nM (lane 1), 100 nM (lane 2), 500 nM (lane 3), and 1000 nM (lane 4) was
added to A375 cells for 4 hours in hypoxia. (D) The mean densitometry data from three independent experiments were normalized to the results obtained in cells in
the absence of Cl-IB-MECA (lane C). Phosphorylation data are shown. Plots are mean ± SE values (n = 3). *P < .01 compared with the control. (E) pp38 protein
levels under A3 receptor stimulation: Cl-IB-MECA at concentrations of 0 nM (lane C), 10 nM (lane 1), 100 nM (lane 2), 500 nM (lane 3), and 1000 nM (lane 4) nM
was added for 4 hours in hypoxia to A375 cells. (F) The mean densitometry data from three independent experiments were normalized to the result obtained in cells
in the absence of Cl-IB-MECA (lane C). Phosphorylation data are shown. Plots are mean ± SE values (n = 3); *P < .01 compared with the control.
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The effects of adenosine on HIF-1a protein accumulation
are not mediated by A1, A2A, or A2B receptors. In support of
this conclusion, DPCPX, SCH 58261, and MRE 2029F20,
adenosine receptor antagonists for A1, A2A, and A2B recep-
tors, respectively, did not block the stimulatory effect of
adenosine on HIF-1a protein increase.
The conclusion that the effects of adenosine on HIF-1a
accumulation are mediated through A3 receptors is sup-
ported by the observation that the stimulatory effects of this
nucleoside on HIF-1a protein are mimicked by the A3 recep-
tor agonist, Cl-IB-MECA, and inhibited by A3 receptor antag-
onists. In particular, the potencies of these drugs are in
agreement with their inhibitory equilibrium binding constant
(Ki) observed in binding experiments for the adenosine A3
receptor [15]. Furthermore, the inhibition of A3 receptor
expression at the mRNA and protein levels is sufficient to
block A3 receptor– induced HIF-1a protein accumulation.
Therefore, our results indicate that the cell surface A3
adenosine receptor transduces extracellular hypoxic signals
into the cell interior.
A3 adenosine receptor stimulation had no effect on HIF-1a
mRNA accumulation, as observed by real-time RT-PCR
experiments. Accordingly, Act-D experiments indicate that
the A3 receptor does not regulate HIF-1a protein expression
through a transcription-dependent mechanism. The lack of
adenosine effect on HIF-1a at the transcriptional level is not
surprising, in view of the fact that hypoxic regulation of HIF-1a
is primarily determined by the stabilization of HIF-1a protein
[50]. In addition, we have obtained evidence that A3 adeno-
sine receptors modulate HIF-1a protein levels through a
translation-dependent pathway while not affecting HIF-1a
oxygen-dependent degradation. Our data suggest that A3
adenosine receptor activation does not increase the half-life
of HIF-1a protein whereas it may increase the rate of HIF-1a
protein synthesis, in a manner similar to the effect of various
growth factors [51,52]. Nevertheless, we cannot exclude the
possibility that A3 adenosine receptor regulates, in hypoxia,
the translation of a protein, which inhibits HIF-1a degradation.
Phosphorylation and dephosphorylation activities have
been suggested to be critical in the signaling pathway
leading to HIF-1 activation. Several reports demonstrated
that hypoxia induces the phosphorylation of HIF-1a by p44/
p42 and p38 MAPKs, which increases both HIF-1a nuclear
localization and transcriptional activity [52,53]. In addition,
adenosine, through A2A receptors, has been shown to di-
rectly enhance MAPK activity in A375 human melanoma
cells [10], but also in nonhuman cell lines stably transfected
with the human A3 receptor [54–56]. In the present study, we
observed that p44/p42 and p38 MAPKs are necessary to
increase HIF-1a levels, but also that these kinases are
included in the molecular signaling pathways generated by
A3 receptor stimulation. Based on these data, we suggest
that adenosine, through A3 receptors, is able to increase the
levels of HIF-1a through p44/p42 and p38 MAPK pathways.
In our previous study on A375 melanoma cells, A3 adenosine
receptor stimulation decreased MAPK activity through the
inhibition of Raf by a PI3K–Akt pathway [57]. However, the
experimental conditions were quite different, being those
experiments performed in normoxia and with high concen-
trations (micromolar) of the A3 receptor agonist. Now, the
concentration of the agonist is nanomolar and the cells are
cultured in hypoxic conditions. These data may explain the
Figure 7. Effect of A3 adenosine receptor stimulation on VEGF and Ang-2 expression in hypoxic A375 cells. (A) VEGF release into culture media from A375 cells
incubated in the absence and in the presence of increasing concentrations of Cl-IB-MECA for 24 hours in hypoxia (reported as ng/ml per 106 cells). (B) Ang-2
release into culture media from A375 cells incubated in the absence and in the presence of increasing concentrations of Cl-IB-MECA for 24 hours in hypoxia
(reported as pg/ml per 106 cells). Plots are mean ± SE values (n = 5). *P < .01 compared with the control (untreated hypoxic cells). (C) HIF-1a silencing by siRNA
transfection. Western blot analysis using an anti –HIF-1a antibody of protein extracts from A375 cells transfected with siRNAHIF-1a by the RNAiFect Transfection
reagent and cultured for 24, 48, and 72 hours in hypoxia. Tubulin shows equal loading protein. (D) Densitometric quantification of HIF-1a Western blot analysis.
Plots are mean ± SE values (n = 5). *P < .01 compared with the control (time 0). (E) Pharmacologic analysis of A3 receptors regulating Ang-2 secretion (reported as
pg/ml per 106 cells). Effects of siRNAHIF-1a, 10 nM A3 receptor antagonist MRE 3008F20, 10 M U0126, and 10 M SB202190 on Ang-2 secretion in the presence
of 500 nM Cl-IB-MECA.
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biphasic effect of Cl-IB-MECA on p42/p44 phosphorylation
levels. Actually, further studies are needed to evaluate the
role of p44/p42 and p38 MAPK in reduced turnover, in-
creased life, and transduction of HIF-1a proteins in hypoxia.
Adenosine A3 receptors are expressed in many different
cell types [7]. To determine whether their effect on HIF-1a
expression was not limited to the A375 cells, we assessed
the ability of Cl-IB-MECA to induce HIF-1a levels in a variety
of cell lines expressing A3 adenosine receptors [7]. We
detected a significant increase in HIF-1a protein expression
through A3 receptors in human keratinocytes (NCTC 2544)
and in different human tumor cells (HT29 colon carcinoma,
MCF-7 breast carcinoma, OVCAR-3 ovarian carcinoma,
U87MG glioblastoma, and U2OS osteosarcoma).
Finally, we decided to look further into the physiological
relevance of the A3 receptor stimulation in hypoxia. HIF-1a is
overexpressed in tumors and is involved in key aspects of
tumor biology, such as invasion, altered energy metabolism,
and angiogenesis [26]. VEGF and Ang-2 are key elements
controlling angiogenesis and are increased in tumors [58].
Adenosine also plays a role in the promotion of angio-
genesis [20,21,59]. The regulation of expression of the an-
giogenic VEGF through adenosine receptors has been
demonstrated in several cell types [22–25]. However, in
our experimental model, there was no effect on VEGF
protein levels following the modulation of HIF-1a induced
by A3 receptor stimulation, indicating that these cells do not
respond to A3 receptor stimulation with an increase in VEGF
and/or that this degree of stimulation is not enough to alter
VEGF protein levels. In particular, the effects of adenosine
on VEGF expression demonstrated in previous works
[22–24] are mediated by A2B adenosine receptors. In addi-
tion, VEGF is coregulated not only by the HIF system, but
also by the AP-1 family of transcription factors possibly
mediated by calcium ions [60]. On the contrary, we demon-
strated for the first time that Ang-2 protein expression was
increased by A3 adenosine receptor stimulation through a
MEK–HIF-1a signaling cascade. Furthermore, these data
confirm that activation of A3 receptors upregulates the ex-
pression of Ang-2, as previously reported [23].
It is recognized that the inhibition of HIF-1 activity repre-
sents a novel therapeutic approach to cancer therapy, es-
pecially in combination with angiogenesis inhibitors, which
would further increase intratumoral hypoxia and thus provide
an even greater therapeutic window for use of an HIF in-
hibitor [57,61]. Recent studies indicate that pharmacologic
inhibition of HIF-1a, and particularly of HIF-regulated genes
important for cancer cell survival, may be more advanta-
geous than HIF gene inactivation therapeutic approaches
[62,63]. Recently, we have demonstrated the mechanisms of
the antiproliferative action of A3 receptor stimulation in A375
normoxic melanoma cells [57]. Now, given the ability of A3
adenosine receptor antagonists to block HIF-1a and Ang-2
protein expression accumulation in hypoxia, our data may
indicate a new approach for the treatment of cancer, based
on the cooperation between hypoxic and adenosine signals,
that ultimately may lead to the increase in HIF-1–mediated
effects in cancer cells.
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